AI Search

Research Assistant

Search across all peptide monographs, dosing protocols, and clinical articles. Type a keyword to find relevant information instantly.

70 items available — type to search

PeptideGrowth Hormone Fragment / Lipolytic Peptide · Fat reduction and body composition improvement (investigational; no regulatory approval for therapeutic use)

AOD-9604

Growth Hormone Fragment - Fat Metabolism Guide

PeptideCytoprotective Pentadecapeptide · Gastrointestinal cytoprotection and mucosal healing (investigational)

BPC-157

Body Protection Compound - Complete Clinical Guide

PeptideGHRH Analog + Growth Hormone Secretagogue (GHS) Combination · Growth hormone deficiency and age-related GH decline (investigational combination)

CJC-1295/Ipamorelin

Growth Hormone Secretagogue Combination - Prescriber Guide

PeptideSynthetic Tetrapeptide (Pineal Gland Bioregulator) · Telomerase activation and telomere maintenance (investigational anti-aging peptide)

Epithalon

Telomerase Activator Peptide - Anti-Aging Guide

PeptideCopper-Binding Tripeptide (Endogenous Regenerative Peptide) · Wound healing and tissue repair (topical and injectable formulations)

GHK-Cu

Copper Peptide Complex - Regenerative Medicine Guide

PeptideMitochondrial-derived metabolic peptide · Investigational metabolic-resilience and insulin-sensitivity support; no FDA-approved indication

MOTs-C

Flagship clinician reference on MOTs-C, covering mechanism, evidence limits, metabolic signaling, and the April 2026 FDA update.

PeptideMelanocortin Receptor Agonist (Cyclic Heptapeptide) · Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved as Vyleesi)

PT-141 (Bremelanotide)

Melanocortin Receptor Agonist - Sexual Dysfunction Guide

PeptideSynthetic Tuftsin Analog / Anxiolytic-Nootropic Peptide · Generalized anxiety disorder and neurasthenia (approved in Russia as intranasal spray)

Selank

Synthetic tuftsin-analog heptapeptide with anxiolytic, nootropic, and immunomodulatory properties

PeptideGLP-1 Receptor Agonist (Incretin Mimetic) · Type 2 diabetes mellitus (FDA-approved: Ozempic, Rybelsus) and chronic weight management (FDA-approved: Wegovy)

Semaglutide

GLP-1 Receptor Agonist - Prescriber Reference

PeptideGrowth Hormone-Releasing Hormone (GHRH) Analog / GH Secretagogue · Growth hormone optimization and anti-aging (off-label via compounding pharmacies)

Sermorelin

Synthetic GHRH(1-29) fragment for physiologic growth hormone optimization

PeptideActin-Sequestering / Regenerative Peptide · Wound healing and tissue repair (investigational; pharmaceutical Tbeta4 in Phase II trials for epidermolysis bullosa and dry eye)

TB-500

Thymosin Beta-4 Fragment - Tissue Repair Guide

PeptideSynthetic GHRH Analog (Growth Hormone-Releasing Hormone) · Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (FDA-approved)

Tesamorelin

GHRH Analog - FDA-Approved Growth Hormone Secretagogue

PeptideImmune-Modulating Thymic Peptide · Chronic hepatitis B (approved in 35+ countries as Zadaxin); immune modulation (compounded use in US)

Thymosin Alpha-1

Immune-Modulating Peptide - Clinical Monograph

PeptideDual GIP/GLP-1 Receptor Agonist (Twincretin) · Type 2 diabetes mellitus (FDA-approved: Mounjaro, 2022) and chronic weight management (FDA-approved: Zepbound, 2023; expanded in 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity)

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist - Clinical Guide

PeptideSmall-molecule NNMT inhibitor (not a peptide; included in peptide-prescribing practice per common co-prescription for metabolic and adipose-targeting protocols) · Investigational metabolic and adipose-targeting agent for obesity, adipose-tissue dysfunction, and related metabolic conditions (no FDA-approved indication; no registered human clinical trials as of April 2026)

5-Amino-1MQ

Investigational metabolic and adipose-targeting agent for obesity, adipose-tissue dysfunction, and related metabolic conditions (no FDA-approved indication; no registered human clinical trials as of April 2026)

PeptideMulti-factor Neuropeptide Preparation (purified free amino acids and low molecular weight neuropeptide fractions <10 kDa) · Neurorehabilitation after ischemic stroke and traumatic brain injury (approved in 35+ countries including Austria, Germany, Russia, China; NOT FDA-approved in the United States)

Cerebrolysin

Neurorehabilitation after ischemic stroke and traumatic brain injury (approved in 35+ countries including Austria, Germany, Russia, China; NOT FDA-approved in the United States)

PeptideEndogenous neuropeptide fragment; hypothalamic reproductive regulator (KISS1/KISS1R pathway) · Investigational stimulation of the hypothalamic-pituitary-gonadal (HPG) axis: diagnostic evaluation of hypogonadotropic hypogonadism, research in fertility induction, and adjunct investigation alongside testosterone replacement therapy (not FDA-approved for any indication)

Kisspeptin-10

Investigational stimulation of the hypothalamic-pituitary-gonadal (HPG) axis: diagnostic evaluation of hypogonadotropic hypogonadism, research in fertility induction, and adjunct investigation alongside testosterone replacement therapy (not FDA-approved for any indication)

PeptideAnti-inflammatory tripeptide; C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH); a melanocortin-family-derived peptide that acts through non-melanocortin-receptor pathways · Investigational anti-inflammatory therapy for inflammatory bowel disease and other chronic inflammatory conditions (no FDA-approved indication)

KPV

Investigational anti-inflammatory therapy for inflammatory bowel disease and other chronic inflammatory conditions (no FDA-approved indication)

PeptidePyridine Dinucleotide Coenzyme (not a peptide; included in peptide-prescribing practice per common co-prescription alongside longevity and metabolic peptides) · Cellular energetics and mitochondrial support in age-related decline, metabolic dysfunction, and post-exertional recovery (all investigational; no FDA-approved indication for injectable NAD+)

NAD+

Cellular energetics and mitochondrial support in age-related decline, metabolic dysfunction, and post-exertional recovery (all investigational; no FDA-approved indication for injectable NAD+)

PeptideTriple-hormone-receptor agonist (GLP-1, GIP, and glucagon receptors) · Chronic weight management and type 2 diabetes (investigational; Phase 3 TRIUMPH program ongoing. NOT FDA-approved as of April 2026)

Retatrutide

Chronic weight management and type 2 diabetes (investigational; Phase 3 TRIUMPH program ongoing. NOT FDA-approved as of April 2026)

Protocol300mcg/day · 12-24 weeks

AOD-9604 — Fat loss / Body composition

Fat loss / Body composition

Protocol250mcg/day · 4-8 weeks

BPC-157 — Gut healing

Gut healing

Protocol250mcg/day · 6-12 weeks

BPC-157 — Injury repair / Musculoskeletal

Injury repair / Musculoskeletal

Protocol100mcg each · Ongoing (cycle 3-6 months on, 1 month off)

Ipamorelin/CJC-1295 — Anti-aging / GH optimization

Anti-aging / GH optimization

ProtocolPRN (as needed) · As needed

PT-141 (Bremelanotide) — Sexual dysfunction

Sexual dysfunction

ProtocolUp to 2.4mg/week · Ongoing

Semaglutide — Weight loss / Obesity

Weight loss / Obesity

Protocol2.5mg weekly · 4-6 weeks loading, then maintenance

TB-500 — Tissue repair / Wound healing

Tissue repair / Wound healing

Protocol2mg/day · 26 weeks (FDA-approved course)

Tesamorelin — Lipodystrophy / Visceral fat reduction

Lipodystrophy / Visceral fat reduction

BlogClinical Pharmacology · 14 min read · 2026-07-18

When Peptide Dose Escalation Makes Sense

Raise peptide doses only after adequate time, measurable partial response, acceptable side effects, and verified adherence.

BlogClinical Pharmacology · 13 min read · 2026-07-17

Liraglutide and GLUT4: Muscle Glucose Uptake

Preclinical data suggest GLP-1 agonists enhance GLUT4 trafficking in insulin-resistant muscle, yet direct human muscle evidence is lacking.

BlogClinical Pharmacology · 15 min read · 2026-07-16

7 Studies on Epitalon, Aging, and Telomeres

Review finds strong cell-level effects, mixed animal results, and weak human evidence—Epitalon remains investigational.

BlogClinical Pharmacology · 20 min read · 2026-07-15

Brown Fat Activation Peptides: 4 Mechanisms

Four peptide-linked routes to activate brown fat - UCP1, mitochondrial heat, browning, and endocrine crosstalk - with modest clinical impact.

BlogClinical Pharmacology · 13 min read · 2026-07-15

Counterfeit Peptides: Risk Review for Prescribers

Guidance for clinicians to verify peptide sources, confirm CoA/sterility, document lots, and stop use when records are missing.

BlogClinical Pharmacology · 14 min read · 2026-07-13

GLP-1 Peptides and Insulin-Mediated Glucose Uptake

GLP‑1 peptides lower glucose mainly via glucose‑dependent insulin, glucagon suppression, and slower gastric emptying; direct muscle uptake in humans is limited.

BlogClinical Pharmacology · 18 min read · 2026-07-06

How to Interpret Peptide Research for Clinical Use

Clinical guide to evaluate peptide evidence, regulatory status, safety, dosing, and sourcing for responsible patient use.

BlogClinical Pharmacology · 22 min read · 2026-07-04

Best Practices for Intramuscular Injection Angles

Practical guide to true 90° IM insertion, correct needle length, site landmarks, Z‑track, and special-population adjustments.

BlogClinical Pharmacology · 15 min read · 2026-07-03

Oxytocin Dosing for Social Impairments

Oxytocin dosing must be matched to patient and study design; 24 IU is the common benchmark, 48 IU shows pooled benefit, and sodium monitoring is essential.

BlogClinical Pharmacology · 14 min read · 2026-07-02

How Peptides Target Cardiovascular Tissues

How peptides plus carrier systems concentrate drugs in heart or vessel lesions—benefits, limits, safety, and clinical checks.

BlogClinical Pharmacology · 14 min read · 2026-07-01

Peptides for Sleep and Brain Recovery: Clinical Insights

Most peptides lack robust human sleep data; approved sleep drugs lead, while Cerebrolysin shows trial evidence but remains investigational.

BlogClinical Pharmacology · 15 min read · 2026-06-22

Regulatory Guidelines for Adverse Event Logs

How peptide clinics should log, classify, escalate, and report adverse events to meet FDA timelines and retain records for 10 years.

BlogClinical Pharmacology · 17 min read · 2026-06-21

Tumor-Targeting Peptides: Mechanisms of Action

How tumor-targeting peptides locate tumors, cross barriers, enter cells, and act via targeting, microenvironment activation, trafficking, or drug delivery.

BlogFunctional Medicine · 18 min read · 2026-06-20

Bioactive Peptides in Lipid Regulation: Key Insights

Review of soy, marine, algae, and animal peptides for cholesterol, triglyceride, and liver-fat control; soy has strongest clinical evidence.

BlogRegenerative Medicine · 18 min read · 2026-06-19

Niche Branding for Regenerative Medicine Clinics

Brand around one patient problem—not a peptide—to improve clarity, ad compliance, patient trust, and recurring revenue.

BlogClinical Pharmacology · 15 min read · 2026-06-18

Common Drug Interactions in Weight Loss Peptides

Peptide weight-loss drugs slow gastric emptying; watch hypoglycemia with diabetes meds, reduced oral contraceptive effect, and thyroid/INR shifts.

BlogClinical Pharmacology · 14 min read · 2026-06-17

Endotoxin Testing Regulations: What Prescribers Need to Know

How prescribers should verify endotoxin limits, COA data, and pharmacy type (503A/503B) before using compounded injectable peptides.

BlogClinical Pharmacology · 17 min read · 2026-06-12

Top 5 Tools for Peptide Batch Calculations

Compare five essential tools for precise peptide reconstitution and dosing: clinical calculators, spreadsheets, apps, pharma tools, and syringe converters.

BlogClinical Pharmacology · 20 min read · 2026-06-11

How Peptides Affect Appetite and Satiety Signals

How gut peptides communicate with the brain to drive hunger and fullness, and how peptide therapies alter appetite and support weight loss.

BlogRegenerative Medicine · 19 min read · 2026-06-10

Peptide Dosing Protocols for Post-Surgery Healing

Guidelines for using BPC-157 and TB-500 after surgery: timing, dosing, safety, and monitoring.

BlogClinical Pharmacology · 19 min read · 2026-06-09

Peptide Delivery Systems: Skin-Specific Innovations

Compare liposomes, hydrogels, microneedles and iontophoresis for safe, targeted peptide delivery across the skin barrier.

BlogClinical Pharmacology · 20 min read · 2026-06-09

Peptide Reconstitution Errors: Causes and Fixes

Avoid peptide dosing, solvent, technique, and storage errors with clear reconstitution steps, calculators, and SOP tips.

BlogFunctional Medicine · 18 min read · 2026-06-07

Peptides for Brain Fog: Mechanisms of Action

Explains how peptides relieve brain fog via anti-inflammatory, mitochondrial, neurotransmitter and vascular mechanisms, plus delivery and safety.

BlogClinical Pharmacology · 16 min read · 2026-06-06

Peptide Dosing: Avoiding GI Side Effects

Start low, titrate slowly, and use diet and hydration to prevent nausea, diarrhea, and constipation during peptide therapy.

BlogClinical Pharmacology · 19 min read · 2026-06-05

Top 7 Trends in Sustainable Peptide Manufacturing

Seven practical trends—renewable materials, greener solvents, energy-efficient synthesis, safer chemistries, and AI—cutting waste in peptide production.

BlogClinical Pharmacology · 17 min read · 2026-06-04

Lab Tests for Evaluating Peptide Therapy Results

Baseline, follow-up, and periodic labs (IGF-1, CMP, CBC, glucose) to safely monitor and adjust peptide therapy.

BlogClinical Pharmacology · 13 min read · 2026-06-02

AI in Peptide Therapy: Benefits and Challenges

How AI speeds peptide therapy research, dosing, and risk checks—boosting efficiency while requiring clinician verification and regulatory vigilance.

BlogRegenerative Medicine · 17 min read · 2026-06-02

Chondroinductive Peptides: Clinical Applications

Overview of chondroinductive peptides for cartilage regeneration: mechanisms, delivery strategies, clinical trials, and translational hurdles.

BlogClinical Pharmacology · 17 min read · 2026-06-01

Emerging Gut-Brain Peptides for Obesity

Overview of multi-agonist gut-brain peptide therapies for obesity, including trial outcomes, mechanisms, and safety considerations.

BlogClinical Pharmacology · 15 min read · 2026-06-01

Ultimate Guide to Peptide Therapy Conferences

Practical guide to choosing, preparing for, and applying insights from peptide therapy conferences for clinicians and researchers.

BlogClinical Pharmacology · 20 min read · 2026-05-30

How to Build a Peptide Protocol for Metabolic Patients

Clinician-led steps to select, dose, monitor, and combine peptides for obesity, type 2 diabetes, and metabolic syndrome.

BlogClinical Pharmacology · 20 min read · 2026-05-29

Peptide Therapy FAQs: Answers for Licensed Prescribers

Practical FAQ for licensed prescribers on patient selection, dosing, safety, and FDA compounding rules for peptide therapy.

BlogClinical Pharmacology · 29 min read · 2026-05-28

Top Peptide Research Updates for Clinicians: 2026 Roundup

2026 clinical summary of peptide advances across weight loss, regeneration, cognition, aesthetics, and immunomodulation.

BlogClinical Pharmacology · 17 min read · 2026-05-27

CJC-1295 vs Ipamorelin: Which GHRH Protocol Fits Best?

Pairing a short-acting GHRH analogue with a ghrelin agonist yields physiological GH pulses that boost recovery, sleep, and body composition.

BlogClinical Pharmacology · 21 min read · 2026-05-26

Peptide Therapy Prescribing Checklist for New Clinicians

Clear checklist for clinicians covering patient evaluation, labs, legal sourcing, dosing, and monitoring of peptide therapies.

BlogClinical Pharmacology · 18 min read · 2026-05-25

Compounded Peptides: Navigating FDA Compliance in 2026

2026 FDA updates tighten rules for compounded peptides: clinical-need documentation, 503A/503B limits, API sourcing, and PCAC reviews.

BlogFunctional Medicine · 18 min read · 2026-05-24

How to Counsel Patients on Peptide Injection Technique

Practical guidance on safe peptide injections: dosing math, reconstitution, storage, site rotation, and sharps disposal.

BlogClinical Pharmacology · 25 min read · 2026-05-24

Semaglutide vs Tirzepatide: Clinical Comparison for Prescribers

Two weekly incretin therapies differ in weight, glycemic control, and long-term safety—prescribe based on cardio‑renal needs vs maximal weight loss.

BlogFunctional Medicine · 32 min read · 2026-05-23

8 Peptide Therapies Gaining Traction in Functional Medicine

Overview of eight peptides used in functional medicine: mechanisms, uses, dosing, and safety considerations.

BlogClinical Education · 8 min read · 2024-12-15

Understanding Peptide Therapy: A Clinical Overview for Prescribers

A comprehensive introduction to peptide therapeutics, their mechanisms of action, and clinical considerations for integration into practice.

BlogRegulatory · 10 min read · 2024-12-10

Regulatory Landscape: What Prescribers Need to Know About Compounded Peptides

Navigate the complex regulatory environment surrounding compounded peptides, including FDA guidelines, state requirements, and best practices for compliance.

BlogClinical Practice · 7 min read · 2024-12-05

Patient Selection Criteria for Peptide Therapy

Evidence-based guidance on identifying appropriate candidates for peptide therapeutics, including assessment protocols and contraindication screening.

Medical Disclaimer

This search tool is provided as an educational resource for healthcare professionals. Search results are drawn from curated clinical content and should not replace professional medical judgment. Always verify information with primary sources and current clinical guidelines.